Suicide is a major cause of death among patients with schizophrenia, with lifetime prevalence estimates over 10 times higher than the general population and a relatively higher suicide risk found in younger age groups of patients. The risk is particularly high in the first episode of the illness and decreases with time after the first hospital admission. Different studies, using different populations and methods, have yielded varying estimates of the suicide rate in schizophrenia. While earlier research has suggested that up to 13% of patients with schizophrenia commit suicide, more recent studies that take into account the variable suicide risk during the life span (a higher risk close to illness onset and thereafter a declining risk) have reported a lifetime suicide mortality of 4%–5%. Nevertheless, this figure remains significantly higher than estimates for the general population, with the mortality gap between the 2 populations increasing over the last decades.

A number of risk factors for suicide in patients with schizophrenia have been identified, including young age, male gender, higher level of education, greater number of prior suicide attempts, presence of depressive symptoms, active hallucinations and delusions, and insight.

Approximately 20%–40% of patients with schizophrenia attempt suicide in their lifetime. Although past suicide attempts are identified as one of the strongest risk factors for completed suicide, epidemiologic data are sparse. Contrary to completed suicide, which was found to be a more common cause of excess mortality in males versus females with schizophrenia, suicide attempts were observed at the same proportion in both sexes. Typically, the attempts are serious and require medical attention.

The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) was an international, multicenter, randomized, large simple trial designed to examine the risk of nonsuicide mortality associated with 2 second-generation antipsychotics, ziprasidone and olanzapine, in the context of usual clinical treatment in the year after initiation of assigned treatment. Large simple trials (pragmatic or practical trials) intend to provide generalizable answers to simple clinical questions without the risk of channeling bias. In the primary analysis of the ZODIAC study, the incidence of nonsuicide mortality within 1 year of initiating pharmacotherapy was 0.91% for ziprasidone and 0.90% for olanzapine; the relative risk was 1.02 (95% CI, 0.76–1.39).

A prespecified statistical analysis plan in the ZODIAC study defined completed and attempted suicides as 1 of the secondary outcomes. Suicide is the leading cause of premature death in schizophrenia. Thus, identifying individuals with schizophrenia who are at high risk for completed suicide or suicide attempts is an important public health, clinical, and research priority. A greater understanding and timely recognition of key risk factors for suicidal events would help focus clinical priorities and resources on highly...
vulnerable patients during critical time periods. Therefore, the aim of the present analysis was to characterize the following subgroups in the ZODIAC study: subjects who completed or attempted suicide and those who did not. An additional aim was to replicate findings on risk factors for completed or attempted suicide previously reported in smaller studies.

**METHOD**

Full details on the ZODIAC study design and methodology are presented elsewhere and briefly summarized here. The ZODIAC was a large simple trial, i.e., the study was conducted with a minimal modification of routine medical care, except for random allocation of subjects in 1:1 fashion to either ziprasidone or olanzapine. Because the trial was aligned with routine medical care, neither the physician nor the subject was blind to treatment allocation; medication regimens and dosing could be changed based on patients' responses to the assigned treatment, and use of concomitant medications, including other antipsychotics, was permitted. The trial was conducted between February 2002 and March 2007. It was registered on ClinicalTrials.gov (identifier: NCT00418171).

Newly treated subjects with schizophrenia as well as those receiving continuing treatment were eligible if their treating psychiatrist was ready to initiate a new antipsychotic medication and would consider using either ziprasidone or olanzapine. Furthermore, they had to be diagnosed as having schizophrenia according to the treating physician’s clinical judgment, to be inpatients or outpatients ≥ 18 years of age, and to provide signed and dated informed consent. Subjects were excluded if they were pregnant or lactating, participating in any other studies involving investigational products concomitantly or within 30 days, had a history of suicide attempt or known suicidal tendencies, were pregnant, or were previously enrolled in this study and remained on randomized treatment. End point information on the participant’s vital status, continued use of the assigned study drug as indicated on study questionnaires, and whether the participant was hospitalized was obtained through follow-up with the treating physician or another designated member of the medical care team. Medical records and other documentation, where applicable, were obtained for end point screening and coding purposes. In the United States, the National Death Index was also searched for information on vital status for participants lost to follow-up. In the event that the participant could not be contacted, his or her alternative contact was used.

The primary outcome measure was nonsuicide mortality; secondary end points included sudden death, suicide, all-cause and cardiovascular mortality, all-cause hospitalization, and hospitalization for arrhythmia (including arrhythmia reported during hospitalization for other reasons), diabetic ketoacidosis, and myocardial infarction. Discontinuation of randomized treatment as recorded on study questionnaires was also a secondary end point.

A scientific steering committee (SSC), data safety monitoring board (DSMB), and end point committee conducted the study oversight. The SSC and DSMB role was to safeguard scientific integrity of the study, participants’ interests, and monitor overall study conduct; full details are described in Strom et al.

The chair of the end point committee, blinded to treatment allocation, reviewed all fatal events and hospitalizations for classification into 1 of 3 categories: a “potential study end point,” “end point with insufficient data,” or “not a potential study end point.” All potential study end points were placed into 1 of 6 categories (myocardial infarction, arrhythmia, sudden death, diabetic ketoacidosis, suicide, or fatal event with other cause) for detailed review and end point determination by end point committee experts in the fields of psychiatry, cardiology, and endocrinology from the regions participating in the study. Two expert coders, blind to treatment allocation, reviewed anonymized records (eg, medical records, laboratory data, hospital discharge or admission notes, and death certificates) specific to each event. A final end point labeling with level of certainty (“definite,” “possible,” “no indication of end point,” and “insufficient data to determine diagnosis”) was assigned for each event according to prespecified algorithms and expert consensus.

The suicide mortality end point algorithm was based on the history of suicide attempt or known suicidal tendencies and description of the event (eg, suicide note, documentation of method used). Events were coded as follows:

- “Suicide, definite” if there were previously documented suicide attempts or a suicide note was discovered, and an accidental cause of death could be excluded.
- “Suicide, possible” if there was suicidal ideation or previous suicide attempt but no suicide note found, and an accidental cause of death could be excluded.
“Suicide, insufficient data” if it was a fatal event without clear documentation to decide either way. Likewise, suicide attempts were coded as follows:

- “Suicide attempt, definite” if there was a nonfatal event with documentation of past attempts or a suicide note was discovered, and an accident could be excluded.
- “Suicide attempt, possible” if there was a nonfatal event with suicidal ideation but no suicide note was discovered or documented, or there had been a previous attempt but no suicide note was discovered or documented. In either case, an accident could be excluded.

All events and methods used for attempted or completed suicide, recorded in the adverse events forms and case notes, were reviewed by one of the authors (W.W.F.) and classified as a “hard” or “soft” method. Hard methods were those involving hanging or any sort of trauma; soft methods included poisoning or drug overdose. This procedure also included adjudication as to whether or not identified cases met criteria for completed suicides or suicide attempts. Case notes as well as information available from all sources were used to make a distinction between suicide attempt and nonsuicidal self-injury.

Statistical Analysis

Baseline demographic and illness characteristics were summarized using descriptive statistics for the subgroups of subjects who completed (yes/no) or attempted suicide (yes/no). The methods used by subjects in completing or attempting suicide were summarized using descriptive statistics. Estimates of suicide (completed or attempted) rates per 100 person-years of exposure, stratified by time statistics. Estimates of suicide (completed or attempted) rates per 100 person-years of exposure, stratified by time.

Overall mortality rates as well as mortality rates due to suicide, those who did appeared to have a shorter illness duration, a higher number of past suicide attempts and of subjects with ≥5 previous hospitalizations, and more frequent baseline usage of antipsychotic or antidepressant medications. Furthermore, subjects who completed suicide had more cardiovascular conditions at baseline and were more likely to be present or past smokers. The age and sex distributions, as well as disease severity assessed by CGI-S ratings, were similar between the 2 subgroups.

Differences in baseline characteristics were also observed between the subjects who attempted suicide versus those who did not. The subjects who attempted suicide were younger and more frequently female, they had a shorter illness duration, and more of them were present or past smokers at baseline. They had more frequent previous hospitalizations (ie, >5 previous hospitalizations) and more frequent previous suicide attempts. However, the 2 groups were similar in terms of illness severity as assessed by CGI-S ratings, frequency of cardiovascular disorders, and baseline use of antipsychotic or antidepressant medications. Distribution of completed and attempted suicides across geographical regions is summarized in Table 2. No further statistical analyses were performed due to the uneven distribution of these geographical regions in the study.

Baseline characteristics of the ziprasidone and olanzapine treatment groups as well as results of the ZODIAC study primary analysis are reported in full detail elsewhere. Overall mortality rates as well as mortality rates due to completed suicide (using both narrow and broad definition) were comparable in both treatment groups.

Analysis of Predictors of Completed or Attempted Suicide

Among all potential baseline risk factors for completed suicide examined, the variables most associated with completed suicide were history of suicide attempts (OR = 2.6; 95% CI, 1.33−5.12) and usage of antidepressant medication (OR = 3.5; 95% CI, 0.84−14.85) (Table 3). History of >5 hospitalizations in the past (OR = 2.1; 95% CI, 1.35−3.31) and history of suicide attempts (OR = 5.0; 95% CI, 3.21−7.76) were the variables most associated with attempted suicide among potential baseline risk factors for suicide attempts.
Methods Used in Completed or Attempted Suicides and Associated Gender Distribution

The use of hard methods was more frequent in completed suicides, as well as in male subjects who completed or attempted suicide, as seen by the descriptive summary of these data in Table 4. In contrast, soft methods were more frequent in attempted suicides and in female subjects who completed or attempted suicide (Table 4).

### Table 2. Distribution of Completed or Attempted Suicides by Geographical Region

<table>
<thead>
<tr>
<th>Region</th>
<th>No. of Subjects</th>
<th>No. of Completed Suicides</th>
<th>No. of Attempted Suicides</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>9,674</td>
<td>14</td>
<td>65</td>
</tr>
<tr>
<td>Latin America</td>
<td>6,492</td>
<td>10</td>
<td>29</td>
</tr>
<tr>
<td>Eastern Europe</td>
<td>1,022</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>Asia</td>
<td>919</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Sweden</td>
<td>47</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

### Table 3. Multivariate Regression Analysis to Evaluate Potential Risk Factors for Completed and Attempted Suicide (model included treatment)

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed suicide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years since diagnosis of schizophrenia</td>
<td>0.9</td>
<td>0.89–0.98</td>
<td>.002</td>
</tr>
<tr>
<td>History of suicide attempts</td>
<td>2.6</td>
<td>1.33–5.12</td>
<td>.005</td>
</tr>
<tr>
<td>Antidepressant medication use</td>
<td>3.5</td>
<td>0.84–14.85</td>
<td>.085</td>
</tr>
<tr>
<td>Attempted suicide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>1.0</td>
<td>0.95–0.99</td>
<td>.009</td>
</tr>
<tr>
<td>Years since diagnosis of schizophrenia</td>
<td>1.0</td>
<td>0.96–1.01</td>
<td>.204</td>
</tr>
<tr>
<td>&gt;5 Hospitalizations in the past</td>
<td>2.1</td>
<td>1.35–3.31</td>
<td>.001</td>
</tr>
<tr>
<td>History of suicide attempts</td>
<td>5.0</td>
<td>3.21–7.76</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Current/past smoker</td>
<td>1.1</td>
<td>0.71–1.65</td>
<td>.709</td>
</tr>
</tbody>
</table>

### Table 4. Use of Hard and Soft Methods for Completed or Attempted Suicide (data reported by treating psychiatrists and captured in the adverse event forms)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Completed Suicide</th>
<th>Attempted Suicide</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N (%)</td>
<td>n/N (%)</td>
</tr>
<tr>
<td>Use of hard or soft method</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hard method</td>
<td>21/35 (60.0)</td>
<td>37/111 (33.3)</td>
</tr>
<tr>
<td>Soft method</td>
<td>8/35 (22.9)</td>
<td>72/111 (64.9)</td>
</tr>
<tr>
<td>Unclear/insufficient data</td>
<td>6/35 (17.1)</td>
<td>2/111 (1.8)</td>
</tr>
<tr>
<td>Use of hard or soft method by gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males using hard method</td>
<td>14/21 (66.7)</td>
<td>23/37 (62.2)</td>
</tr>
<tr>
<td>Males using soft method</td>
<td>3/8 (37.5)</td>
<td>30/72 (41.7)</td>
</tr>
</tbody>
</table>

4Hard method equals hanging, trauma.
5Soft method equals poison, drugs.
N represents the total number of events.

### Person-Time on Assigned Treatment Analysis

The estimated rates of completed suicides per 100 person-years of exposure were highest in subjects diagnosed with schizophrenia for ≤3 years ago, ie, in subjects early in the illness course (Table 5).

The analyses performed on the 2 medication groups in the ZODIAC trial (ziprasidone, n = 9,077; olanzapine, n = 9,077) yielded similar results as the ones obtained in the overall analysis, without any between-treatment group differences (results not shown).

### DISCUSSION

Previously published results of the ZODIAC trial primary analysis showed that, in this large simple trial that prospectively followed up >18,000 subjects diagnosed with schizophrenia for 1 year, suicide-related mortality was low
(0.19%, or 0.23% when a broadly defined end point was applied). The respective incidence for suicide attempts was 0.54%. In our person-time on assigned treatment analysis, rates of completed and attempted suicides calculated per 100 person-years of exposure remained low (0.24 and 0.74, respectively), with the highest suicide-related mortality among subjects recently diagnosed with schizophrenia (≤ 3 years ago), ie, in subjects early in their illness course. The highest rates of attempted suicides were seen in subjects diagnosed with schizophrenia > 3 and ≤ 5 years ago. We further expanded the primary study analyses by performing an exploratory logistic regression analysis, which showed that, in our cohort, history of suicide attempts, high CGI-S score at baseline, baseline presence of cardiovascular disorders, and the baseline use of antipsychotic or antidepressant medication were all associated with an increased risk for completed suicide (see Table 2) during 1 year from baseline. History of previous suicide attempts, ≥ 5 hospitalizations in the past, and current/past smoking (see Table 3) were associated with an increased risk for suicide attempt. In our cohort, hard methods were more frequently used among completers and male subjects (both completers and attempters); soft methods were more frequent among attempters and female subjects (both completers and attempters).

Data from the ZODIAC study are similar to that reported in the Sertindole Cohort Prospective Study (SCoP), a prospective study focused on cardiac outcomes among 9,809 subjects with schizophrenia randomized to sertindole or risperidone within the clinical practice setting (0.21 and 0.28 per 100 person-years of exposure for sertindole and risperidone, respectively).22 However, the rates reported in the SCoP and ZODIAC trials were low when compared with pooled results23 of 5 studies commonly cited in the literature, yielding an average suicide mortality rate among persons with schizophrenia of 0.49 per 100 subject-years in a total population of 26,991 subjects. It is possible that patient characteristics (ie, more chronic disease, proportion of female participants) and factors associated with clinical study participation (ie, increased attention or social support) may have impacted the results. However, in ZODIAC, the proportion of female participants was similar to that in other studies in schizophrenia. Further, the trial designs of ZODIAC and SCoP mimicked usual clinical care after randomization, which may have minimized the effect of nonspecific trial participation-related factors. Timing of the studies also challenges comparisons between the 5 seminal trials, SCoP, and the ZODIAC trial.

Our results were obtained in > 18,000 subjects participating in the ZODIAC trial, which is the largest sample of subjects with schizophrenia to date in which completed or attempted suicides were prospectively studied. Our cohort was recruited internationally, representing several regions with diverse levels of development and psychiatric care. Furthermore, the analyses presented here are based on predefined secondary outcomes of the ZODIAC trial. In addition to the conventional method of registering serious adverse events and deaths throughout the study, we also applied an independent and blinded adjudication on a case-by-case basis to elucidate and verify each reported case of a potential completed or attempted suicide. The statistical analyses took into account the numbers of cases obtained through standard reporting of completed or attempted suicides as well as those obtained in the most conservative approach to adjudication. Nevertheless, the results obtained in either approach were similar.

Our findings are also validated by the fact that we could replicate a number of results described in earlier, smaller studies. Similar to other authors, we found the highest suicide rates among subjects early in their course of illness. History of prior suicide attempts, identified in the literature as a risk factor for completed suicide, was also replicated in our analysis. Presence of active psychotic or depressive symptoms at baseline has been identified as a risk factor for completed suicide in schizophrenia. However, as none of the symptom-specific psychiatric rating scales was employed at the baseline assessment in ZODIAC, it can only be speculated that baseline use of antidepressants identified in our study may represent a proxy for the presence of active depressive symptoms, while baseline use of antipsychotics may be a proxy for active psychotic symptoms. Lack of any baseline symptom-specific assessments in ZODIAC, therefore, limits any further conclusions.

Well recognized risk factors for suicide attempts such as female gender, history of suicide attempts, a large number of prior psychiatric hospitalizations, or heavy smoking have also been previously documented and replicated in our analysis. The relationships between hard methods, completed suicide, and male gender are well recognized in subjects with schizophrenia. An additional value of the ZODIAC trial is the fact that it is among a few trials that prospectively studied hard outcomes (in this case completed and attempted suicide) in a population with a high risk for such outcomes (ie, subjects with schizophrenia). There were several limitations to our study. The ZODIAC was a large simple trial, and, consequently, only limited clinically relevant information was gathered at a few time points during the 1-year follow-up. Subsequently, only a finite number of baseline variables could be included...
into the exploratory logistic regression analysis. As such, other clinically relevant factors associated with increased risk for a completed or attempted suicide (eg, concurrent substance use disorders or presence of active psychotic or depressive symptoms at baseline) were not evaluable. In addition, we did not systematically collect information on subjects’ medication status at the time of completed or attempted suicide. Thus, we could neither shed light on potential relationships that could have existed between the current medication and suicidality nor elucidate a potential protective effect ziprasidone or olanzapine may have against suicidality behavior. Therefore, the potential relationship between ongoing treatment with either ziprasidone or olanzapine and suicidality in subjects with schizophrenia needs further investigation in future studies. An analysis based on geographic region was not performed due to overrepresentation of subjects from some regions. While the ZODIAC employed naturalistic follow-up, randomization was used, which may have affected the generalizability of the study population. A low overall number of observed events (35 completed suicides and 108 suicide attempts) could have impacted the risk factor analyses and should be taken into account when results are interpreted. Further, the ratio between attempted versus completed suicides during the 1-year study period was 3:1, which may suggest possible underreporting of suicide attempts. However, as previously reported in a Pfizer-sponsored analysis of suicidality events within randomized clinical studies of ziprasidone, which were mostly of short-term (up to 6 weeks) duration, no completed suicides and only 2 suicide attempts were reported among 1,122 ziprasidone-treated subjects with schizophrenia. Furthermore, baseline usage of antidepressants reported in the ZODIAC was low: only 2 of the 35 completers and 2 of the 108 attempters were treated with antidepressants. This finding may be at odds with literature showing that history of past and present depressive disorders had a strong association with suicide in schizophrenia, while a depressive disorder was suggested to act as a trigger for suicidal behavior in vulnerable patients with schizophrenia. Our article focused on evaluating potential risk factors for completed and attempted suicides. Accordingly, a pool of potential risk factors was identified and analyzed using separate logistic regression models, and the resulting subset of risk factors was included in a multivariate model describing their relationship with the odds of completing or attempting suicide. The results of this statistical analysis are presented in Table 3, along with P values. With regard to the data presented in Tables 1, 2, 4, and 5, the intent was to provide only a descriptive summary. Formal inferential analysis of the data presented in these tables was not the focus of the analysis and, hence, out of the scope for this article.

In summary, our results, obtained in a large, prospective randomized study in subjects with schizophrenia, confirm and expand the knowledge about completed or attempted suicide in schizophrenia as well as the risk factors associated with such events.

### Drug names:
- olanzapine (Zyprexa and others), risperidone (Risperdal and others), ziprasidone (Geodon and others).

### Author affiliations:
- Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Innsbruck, Austria (Dr Fleischhacker); Zucker Hillside Hospital, Glen Oaks (Dr Kane); Pfizer Inc, New York (Drs Geier, Karayal, Kolluri, Eng, and Reynolds); New York; and Department of Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia (Dr Strom).

### Author contributions:
All authors contributed substantially to the conception and design, or acquisition of data, or analysis and interpretation of the data. All authors were involved in drafting and revising the manuscript for important intellectual content, and all authors approved the final version to be published.

### Potential conflicts of interest:
Dr Fleischhacker has received research grants from Alkermes, Janssen, Otsuka, and Reckitt-Benckiser; has received consulting honoraria from Amgen, Bristol-Myers Squibb, Endo, Janssen, Lundbeck, MedAvante, Otsuka, Pfizer, Richter, Roche, Sunovion, and Vanda; has received speaker honoraria from AstraZeneca, Endo, Janssen, Lundbeck, Otsuka, Richter, and Roche; and owns MedAvante stocks.

Dr Kane has served as a consultant to Pfizer in connection with the scientific oversight of the study and has served as a consultant and speaker to and has received honoraria from Abbott, Alkermes, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingehelm, Cephalon, Dainippon Sumitomo, Eisai, Eli Lilly, Forrest, Genetech, Intracelular Therapeutics, Janssen, Johnson & Johnson, Lundbeck, Merck, Myriad, Novartis, Otsuka, Pfizer, Proteus Biomedical, Roche, Rules Based Medicine, Sunovion, Takeda, Targcept, Vanda, and Wyeth; and is a MedAvante shareholder.

Drs Geier, Karayal, Kolluri and Reynolds are employees and shareholders of Pfizer, the maker and manufacturer of ziprasidone, as was Dr Eng at the time the study was conducted.

Dr Strom is now an employee of Rutgers University, and was an employee of the University of Pennsylvania, which received financial support from Pfizer in connection with the scientific oversight of the study and the development of this article. He also served as a consultant to Pfizer on topics not related to this study. In the past 12 months, he has consulted for Amgen, Bristol-Myers Squibb, Endo, GlaxoSmithKline, Lundbeck, Novartis, Roche, and Sanofi on topics unrelated to this study.

### Funding/support:
This study was supported in full by funding from Pfizer, Inc, New York, New York.

### Previous presentations:
Partial results were previously presented at the International Congress on Schizophrenia Research (ICOSR); March 28–April 1, 2009; San Diego, California●163rd American Psychiatric Association Annual Meeting; May 22–26, 2010; New Orleans, Louisiana.

### Acknowledgments:
The authors acknowledge the efforts of all investigators and subjects participating in the ZODIAC; Vito Calamia, MS, Pfizer, Inc, New York, New York, for statistical analyses performed in connection with this study; Milana Zivkov, MD, consultant, Treigr, Croatia, in providing editorial support, revising the paper based on author feedback and styling the paper for journal submission; and Mark Olfson, MD, Columbia University, New York, New York, for critical review of the paper. Mr Calamia is an employee and shareholder of Pfizer, the maker and manufacturer of ziprasidone.

Dr Zivkov was a paid consultant to Pfizer in connection with the scientific oversight of this study. In the past 12 months, he has consulted for Amgen, Bristol-Myers Squibb, Endo, GlaxoSmithKline, Lundbeck, Novartis, Roche, and Sanofi on topics unrelated to this study.

### REFERENCES:


